EMD Millipore, the life science division of Merck KGaA, has announced an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates.
The insulin is of non-animal origin and will be marketed under EMD Millipore’s CellPrime brand name, complementing the company’s range of non-animal origin supplements for cell culture biomanufacturing.
“CellPrime Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety,” said Burghard Freiberg, senior vice president of pharm chemicals solutions. “Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective.”
EMD Millipore chose Julphar Diabetes as its source for recombinant human insulin because the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency.